ORAL PRESENTATIONS: Thursday 23 June: Hepatitis C: Clinical aspects and therapy| Volume 77, SUPPLEMENT 1, S16-S17, July 01, 2022

Glecaprevir/pibrentasvir and sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen

      This paper is only available as a PDF. To read, Please Download here.